Project Grant R01AG092496
- Federal Grant Award Summary Award Overview New York University School of Medicine received a $712,578 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) effective February 1, 2026, through December 31, 2030. This prospective research study investigates the relationship between viral infections and Alzheimer's disease (AD) risk in aging populations, addressing a critical public health gap as AD prevalence is projected to triple to 13 million cases in the...
- Federal Grant Award Summary New York University School of Medicine received a $642,063 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective January 15, 2026, with completion targeted for December 31, 2030. The award supports a collaborative research investigation examining gabaergic microcircuits in the hippocampal CA1 region to identify cellular targets and neuromodulatory mechanisms for early-stage Alzheimer's disease (AD)...
- Federal Grant Award Summary Northwestern University's Sponsored Research Division received a $148,050 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to conduct research investigating sex-specific hypothalamic pathology and immune infiltration in Alzheimer's Disease (AD). The award, initiated on September 27, 2025, and concluding May 31, 2028, supports a three-year research initiative addressing the significant sex disparity in AD...
- Federal Grant Award Summary New York University was awarded $1,049,816 through the National Institute on Aging's Aging Research program (CFDA 93.866) effective May 15, 2025, with a completion date of January 31, 2029. This project grant supports the development of statistical methodologies to improve the estimation and prediction of Alzheimer's disease (AD) progression using longitudinal cohort study data. The research addresses critical gaps in current analytical approaches by developing...
- Federal Project Grant Award Summary New York University School of Medicine received a $130,302 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective July 15, 2025, with an ultimate completion date of March 31, 2030. This research award supports a multi-aim investigation into the selective vulnerability of basal forebrain cholinergic neurons (BFCNs) to tau pathology in Alzheimer's disease. The project will deliver scientific...
- Summary New York University School of Medicine received a $3.1 million Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective September 15, 2025 through May 31, 2030. The award supports a multidisciplinary research initiative examining the relationship between peripheral immune dysfunction and vascular contributions to cognitive decline and dementia. The research integrates biofluid biomarkers—specifically platelet aggregation,...
- Federal Grant Award Summary New York University received a $1,012,879 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 5, 2025, with completion anticipated by August 31, 2029. The award supports the development of three novel statistical machine learning methods designed to enhance the understanding, diagnosis, and prediction of Alzheimer's disease using multi-view data integration. The primary deliverables include: (1) a...
- Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $839,933 under the Aging Research program (CFDA 93.866), effective September 1, 2025, through May 31, 2030. This award supports research investigating the role of N6-methyladenosine (M6A) RNA modifications in microglial dysfunction and Alzheimer's disease pathogenesis. The research will systematically map M6A RNA modification landscapes in microglia...
- Federal Project Grant Award Summary Albert Einstein College of Medicine received a $462,000 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), effective August 15, 2025, with a completion date of July 31, 2027. The award supports a two-pronged investigation into the regulation of thymus function and aging by the sympathetic nervous system (SNS). The research will map the distribution and functional role of beta-adrenergic...
- Federal Grant Award Summary Albert Einstein College of Medicine received a $336,000 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded September 1, 2025, with a completion date of August 31, 2027. The project evaluates self-reported subjective cognitive concerns (SCC) as an early screening tool for Alzheimer's disease by assessing their relationship with longitudinal Alzheimer's disease biomarkers in a diverse, non-demented older adult...
Award Details: New York University School of Medicine received a $724,813 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective January 1, 2026, through November 30, 2030. The award supports prospective research investigating the relationship between midlife circulating autoantibodies (AAbs) and Alzheimer's disease (AD) risk in women. Research Objectives and Products: This project addresses a critical gap in AD research by conducting the first prospective longitudinal study examining associations between autoantibody profiles measured at midlife and subsequent AD development in women. The research will identify and characterize AAbs that may serve as early biomarkers of AD susceptibility, with particular focus on distinguishing pathogenic autoantibodies from protective natural autoantibodies. Given that women comprise nearly two-thirds of Americans age 65 and older with AD and demonstrate distinct immunological characteristics, this study will generate evidence-based findings on immune system components related to AD risk in women. Expected deliverables include biomarker data, epidemiological findings on midlife AAb associations with AD outcomes, and foundational knowledge to support early risk stratification and prevention strategies during the preclinical phase of disease onset.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $724.8k | 1/27/26 |